Ngenla (Somatrogon-ghla)

Ngenla (somatrogon-ghla) is a once-weekly human growth hormone (hGH) analog used in the treatment of pediatric patients aged three years and more who have growth failure because of poor secretion of endogenous growth hormone.

Recommended Dosage: The recommended dosage of Ngenla injection is 0.66 mg per kg based on actual body weight administered once weekly by subcutaneous (SC) injection, on the same day every week, at any time of the day in the upper arms, abdomen, buttocks, or thighs.

The dosage can be individualized for each patient on behalf of the growth response. If necessary, the day of weekly administration can be changed as long as the time between a couple of doses is at least 3 days. After considering a fresh dosing day, the once-weekly dosing should be continued. When switching from daily growth hormone, the once-weekly dose may be started on the day after their final daily injection. If more than 1 injection is needed to deliver a complete dose, each injection needs to be administered at a dissimilar injection site.

If a dose is missed, administer it as quickly as possible within 3 days following the missed dose. If more than 3 days have elapsed, skip the missed dose and administer the next scheduled dose on the regularly scheduled day.

• Treatment with Ngenla 24 mg/1.2 mL (20 mg/mL) or 60 mg/1.2 mL (50 mg/mL) injection should be supervised by a health specialist who is experienced in the diagnosis and management of pediatric patients aged three years and more with growth failure because of growth hormone deficiency (GHD).
• Fundoscopic examination must be performed before initiating treatment with Ngenla injection to exclude preexisting papilledema. In case papilledema is suspected, assess the etiology and treat the underlying cause prior to initiating this treatment.
• Serious systemic hypersensitivity reactions (such as anaphylaxis, angioedema) may occur with somatropin. A prompt medical help should be sought if allergic reactions occur. Ngenla is not for patients with known hypersensitivity to somatrogon or any existing excipients in Ngenla.
• Ngenla treatment may reduce insulin sensitivity, mainly at higher doses. Monitor glucose levels periodically, mainly in those with risk factors for diabetes mellitus, such as Turner syndrome, obesity, or a family history of diabetes mellitus. Individuals with preexisting type 1/2 diabetes mellitus or pre-diabetes needs to be evaluated closely.

What documents are required to import NGENLA to India?

NGENLA (somatrogon-ghla) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

NGENLA (somatrogon-ghla injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Ngenla in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of NGENLA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ngenla price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Ngenla®?

Somatrogon-ghla is a Generic Name for the trade name drug Ngenla®.

What is the Manufacturer’s Name of Ngenla®?

Ngenla® is manufactured by Pfizer Pharmaceuticals.

Is Ngenla® approved by the FDA?

Yes, Ngenla® is approved by the FDA. Date of approval: June 27, 2023.

Where can I get Ngenla® at the best price in India?

To get the best Ngenla price in India, kindly connect with the Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Ngenla®, a medical prescription is required from a treating physician.

What is the dosage and form of Ngenla® supplied?

Ngenla® is supplied as Injections: 24 mg/1.2 mL (20 mg/mL) and 60 mg/1.2 mL (50 mg/mL) single-patient-use prefilled pen for subcutaneous use. 

What are the most common side effects of Ngenla®? 

The most common side effects of Ngenla® are headache, injection site reactions, nasopharyngitis, rash, hypothyroidism, pyrexia, cough, vomiting, anemia, abdominal pain, and oropharyngeal pain.

How much does Ngenla® cost in India?

The cost of Ngenla in India can vary. In order to procure this medication legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Ngenla®?

Store refrigerated at 36-46°F (2-8°C) in the original carton to protect from light. Do not freeze or shake it. Avoid using it if it has been frozen. Place it away from direct sunlight.

Is it safe to buy Ngenla® online in India?

Yes, one can buy Ngenla online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Ngenla® is not (yet) registered or available in your country. We can help facilitate the supply of Ngenla® through legal channels.